Vous n'êtes pas connecté
KalVista announces FDA acceptance of New Drug Application for sebetralstat for oral on-demand treatment of hereditary angioedema KalVista Pharmaceuticals announced that the US Food and Drug Administration (FDA) has accepted its New Drug Application (NDA) for sebetralstat, a novel, investigational oral plasma kallikrein inhibitor for the on-demand treatment of hereditary angioedema (HAE) attacks in [...]
The FDA accepts Axsome's resubmission of the NDA for AXS-07 for the acute treatment of migraine. A decision is due on Jan. 31, 2025. Shares rise.
Intellia Therapeutics to present data from the Phase 2 study of NTLA-2002 for the treatment of hereditary angioedema (HAE) at the 2024 ACAAI Annual...
Medexus Pharmaceuticals (TSX:MDP) reveals the U.S. FDA has extended the review period for the company's new drug application for treosulfan.
Medexus Pharmaceuticals (TSX:MDP) reveals the U.S. FDA has extended the review period for the company's new drug application for treosulfan.
BioCryst presents new Orladeyo (berotralstat) data at 7th Bradykinin Symposium BioCryst Pharmaceuticals today announced the presentation of six...
INDIANAPOLIS, Sept. 13, 2024 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) announced today the U.S. Food and Drug Administration (FDA) approved...
Pharvaris provides business update and expands development program for deucrictibant Pharvaris today announced: The planned initiation of CHAPTER-3,...
KalVista Pharmaceuticals Presents Sebetralstat Data at Bradykinin Symposium 2024 KalVista Pharmaceuticals announced that it presented additional...